{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:43:41Z","timestamp":1791848621556,"version":"4.3.4"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Glaukos Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vision"],"abstract":"<jats:p>This multicenter study evaluated the effectiveness and safety of third-generation trabecular micro-bypass implantation (iStent\u00ae infinite) combined with phacoemulsification (n = 233 eyes). Key outcomes through 12 months included the mean change in intraocular pressure (IOP) and the number of topical medications, as well as proportions achieving IOPs \u2264 18\/15\/12 mmHg or using 0\/1\/2\/ \u2265 3 medications. In all eyes with 12-month follow-up data (n = 96, consistent cohort), the mean IOP reduced from 17.2 \u00b1 4.2 mmHg preoperatively to 13.8 \u00b1 3.0 mmHg at Month 12 (p = 0.001), while the mean number of medications reduced from 1.24 \u00b1 0.91 preoperatively to 0.61 \u00b1 0.96 at Month 12 (p = 0.001). The proportions of eyes achieving IOP \u2264 18\/15\/12 mmHg increased from 63.5%, 34.4%, and 14.6% preoperatively to 92.7%, 71.9%, and 37.5%, respectively at Month 12, (all p = 0.001). The proportions of eyes off medication increased from 16.7% preoperatively to 62.5% at Month 12 (p = 0.001). This study provides clinically relevant, real-world results that demonstrate significant reductions in IOP and the number of topical glaucoma medications required following iStent infinite trabecular micro-bypass and phacoemulsification.<\/jats:p>","DOI":"10.3390\/vision9030061","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T09:33:53Z","timestamp":1753090433000},"page":"61","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Third-Generation Trabecular Micro-Bypass Implantation and Phacoemulsification in Patients with Glaucoma: A Multicenter Study"],"prefix":"10.3390","volume":"9","author":[{"given":"Mitchell","family":"Shultz","sequence":"first","affiliation":[{"name":"Shultz-Chang Vision, 18350 Roscoe Blvd #101, Northridge, CA 91325, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary M.","family":"Vest","sequence":"additional","affiliation":[{"name":"Mile High Eye Institute, Sheridan, CO 80110, USA"},{"name":"Rocky Vista University, Englewood, CO 80112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Trubnik","sequence":"additional","affiliation":[{"name":"Ophthalmic Consultants of Long Island, Manhasset, NY 11030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-2720","authenticated-orcid":false,"suffix":"Jr.","given":"Steven R.","family":"Sarkisian","sequence":"additional","affiliation":[{"name":"Oklahoma Eye Surgeons, PLLC, Oklahoma City, OK 73112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Hornbeak","sequence":"additional","affiliation":[{"name":"Glaukos Corporation, Aliso Viejo, CA 92656, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"ref_1","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators, and Vision Loss Expert Group of the Global Burden of Disease Study (2021). Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health, 9, e144\u2013e160."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/ICL.0000000000000544","article-title":"Ocular surface disease and glaucoma medications: A clinical approach","volume":"45","author":"Zhang","year":"2019","journal-title":"Eye Contact Lens"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","article-title":"Adherence and persistence with glaucoma therapy","volume":"53","author":"Schwartz","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"ref_6","first-page":"4638","article-title":"Geographic Disparities in Glaucoma Surgical Care: An Intelligent Research in Sight (IRIS) Registry Analysis","volume":"65","author":"Lokhande","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ophtha.2019.03.006","article-title":"Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results","volume":"126","author":"Samuelson","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ogla.2024.02.004","article-title":"Prospective, Randomized Controlled Trial of Cataract Surgery vs Combined Cataract Surgery With Insertion of iStent Inject","volume":"7","author":"Bigirimana","year":"2024","journal-title":"Ophthalmol. Glaucoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/IJG.0000000000001716","article-title":"Three-Year Outcomes of Second-generation Trabecular Micro-bypass Stents (iStent inject) With Phacoemulsification in Various Glaucoma Subtypes and Severities","volume":"30","author":"Salimi","year":"2021","journal-title":"J. Glaucoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2147\/OPTH.S373290","article-title":"Multicenter Effectiveness and Disease Stability Through 3 Years After iStentTrabecular Micro-Bypass with Phacoemulsification in Glaucoma and Ocular Hypertension","volume":"16","author":"Clement","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s12325-024-02788-y","article-title":"7-Year Efficacy and Safety of iStent inject Trabecular Micro-Bypass in Combined and Standalone Usage","volume":"41","author":"Hengerer","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/IJG.0000000000002141","article-title":"Effectiveness and safety of iStent infinite trabecular micro-bypass for uncontrolled glaucoma","volume":"32","author":"Sarkisian","year":"2023","journal-title":"J. Glaucoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ophtha.2010.07.007","article-title":"Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract","volume":"118","author":"Samuelson","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/IJG.0000000000001805","article-title":"Standalone iStent Trabecular Micro-bypass Glaucoma Surgery: A Systematic Review and Meta-Analysis","volume":"30","author":"Healey","year":"2021","journal-title":"J. Glaucoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40123-024-01087-7","article-title":"Third-Generation Trabecular Micro-Bypass Implantation with Phacoemulsification for Glaucoma","volume":"14","author":"Vest","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e001575","DOI":"10.1136\/bmjophth-2023-001575","article-title":"Rates of visual field change and functional progression in glaucoma following trabecular microbypass implantation of iStent technologies: A meta-analysis","volume":"9","author":"Gillmann","year":"2024","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40123-025-01126-x","article-title":"Six-Month Outcomes from a Prospective, Randomized Study of iStent infinite Versus Hydrus in Open-Angle Glaucoma: The INTEGRITY Study","volume":"14","author":"Ahmed","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","article-title":"The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study","volume":"127","author":"Niziol","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5301\/EJO.2010.6112","article-title":"Do adherence rates and glaucomatous visual field progression correlate?","volume":"21","author":"Rossi","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.2147\/OPTH.S439457","article-title":"Alternatives to Topical Glaucoma Medication for Glaucoma Management","volume":"17","author":"Bedrood","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"ref_21","first-page":"986","article-title":"Long-Term Chronic Drop Therapy vs. Intracameral Procedural Pharmaceuticals for Glaucoma: What Does the Evidence Support?","volume":"15","author":"Kamat","year":"2024","journal-title":"J. Clin. Exp. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/17469899.2023.2199981","article-title":"Emerging glaucoma treatments: Are we seeing an improvement in adherence?","volume":"18","author":"Droste","year":"2023","journal-title":"Expert Rev. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s40123-023-00831-9","article-title":"Challenging the \u201cTopical Medications-First\u201d Approach to Glaucoma: A Treatment Paradigm in Evolution","volume":"12","author":"Radcliffe","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","article-title":"The most common barriers to glaucoma medication adherence: A cross-sectional survey","volume":"122","author":"Robin","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.007","article-title":"Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI From the iStent inject\u00ae Pivotal Trial","volume":"229","author":"Samuelson","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/jop.2011.0159","article-title":"Ocular surface disease and glaucoma: How to evaluate impact on quality of life","volume":"29","author":"Rossi","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."}],"container-title":["Vision"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2411-5150\/9\/3\/61\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:12:32Z","timestamp":1760033552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2411-5150\/9\/3\/61"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["vision9030061"],"URL":"https:\/\/doi.org\/10.3390\/vision9030061","relation":{},"ISSN":["2411-5150"],"issn-type":[{"value":"2411-5150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]}}}